JP2006528152A5 - - Google Patents

Info

Publication number

JP2006528152A5

JP2006528152A5 JP2006520797A JP2006520797A JP2006528152A5 JP 2006528152 A5 JP2006528152 A5 JP 2006528152A5 JP 2006520797 A JP2006520797 A JP 2006520797A JP 2006520797 A JP2006520797 A JP 2006520797A JP 2006528152 A5 JP2006528152 A5 JP 2006528152A5

Authority

JP

Japan

Prior art keywords

calcitonin

agent

pharmaceutical composition

treatment

osteoarthritis

Prior art date

2004-07-22

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical group N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 36
• 102000055006 Calcitonin Human genes 0.000 claims description 27
• 108060001064 Calcitonin Proteins 0.000 claims description 27
• 229960004015 calcitonin Drugs 0.000 claims description 27
• 229960003773 calcitonin (salmon synthetic) Drugs 0.000 claims description 7
• 108010068072 salmon calcitonin Proteins 0.000 claims description 7
• 239000000203 mixture Substances 0.000 claims description 6
• 239000008194 pharmaceutical composition Substances 0.000 claims description 6
• 238000010521 absorption reaction Methods 0.000 claims description 3
• 238000004519 manufacturing process Methods 0.000 claims description 3
• 229920000642 polymer Polymers 0.000 claims description 2
• 239000003795 chemical substances by application Substances 0.000 claims 17
• 201000008482 osteoarthritis Diseases 0.000 claims 6
• 229940124447 delivery agent Drugs 0.000 claims 5
• 230000002265 prevention Effects 0.000 claims 5
• 239000003814 drug Substances 0.000 claims 3
• 239000008203 oral pharmaceutical composition Substances 0.000 claims 3
• XUHVCHNJCBBXMP-UHFFFAOYSA-M sodium;10-[(2-hydroxybenzoyl)amino]decanoate Chemical compound [Na+].OC1=CC=CC=C1C(=O)NCCCCCCCCCC([O-])=O XUHVCHNJCBBXMP-UHFFFAOYSA-M 0.000 claims 3
• UOENJXXSKABLJL-UHFFFAOYSA-M sodium;8-[(2-hydroxybenzoyl)amino]octanoate Chemical compound [Na+].OC1=CC=CC=C1C(=O)NCCCCCCCC([O-])=O UOENJXXSKABLJL-UHFFFAOYSA-M 0.000 claims 3
• XRTHAPZDZPADIL-UHFFFAOYSA-N 8-[(5-chloro-2-hydroxybenzoyl)amino]octanoic acid Chemical compound OC(=O)CCCCCCCNC(=O)C1=CC(Cl)=CC=C1O XRTHAPZDZPADIL-UHFFFAOYSA-N 0.000 claims 2
• QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims 2
• 230000009102 absorption Effects 0.000 claims 2
• 239000003623 enhancer Substances 0.000 claims 2
• 239000002702 enteric coating Substances 0.000 claims 2
• 238000009505 enteric coating Methods 0.000 claims 2
• 229940078581 Bone resorption inhibitor Drugs 0.000 claims 1
• 239000000969 carrier Substances 0.000 claims 1
• 239000003085 diluting agent Substances 0.000 claims 1
• XGSDAQOSOKPJML-UHFFFAOYSA-L disodium;8-[(5-chloro-2-oxidobenzoyl)amino]octanoate Chemical compound [Na+].[Na+].[O-]C(=O)CCCCCCCNC(=O)C1=CC(Cl)=CC=C1[O-] XGSDAQOSOKPJML-UHFFFAOYSA-L 0.000 claims 1
• 229940079593 drug Drugs 0.000 claims 1
• 230000004060 metabolic process Effects 0.000 claims 1
• 230000011164 ossification Effects 0.000 claims 1
• 230000009103 reabsorption Effects 0.000 claims 1
• 210000005065 subchondral bone plate Anatomy 0.000 claims 1
• WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 15
• 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 7
• 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 7
• 229960000913 crospovidone Drugs 0.000 description 6
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
• 229940069328 povidone Drugs 0.000 description 5
• 241001465754 Metazoa Species 0.000 description 3
• 238000009472 formulation Methods 0.000 description 3
• 238000000034 method Methods 0.000 description 3
• 230000037396 body weight Effects 0.000 description 2
• 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 2
• 150000003839 salts Chemical group 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
• 229920003085 Kollidon® CL Polymers 0.000 description 1
• 241000316144 Macrodon ancylodon Species 0.000 description 1
• 229920003075 Plasdone™ K-29/32 polymer Polymers 0.000 description 1
• 229920003072 Plasdone™ povidone Polymers 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 150000001875 compounds Chemical class 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 229920001519 homopolymer Polymers 0.000 description 1
• 229940060367 inert ingredients Drugs 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 239000006186 oral dosage form Substances 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• 229920001059 synthetic polymer Polymers 0.000 description 1
• 238000010998 test method Methods 0.000 description 1